Depot-specific adipocyte cell lines reveal differential drug-induced responses of white adipocytes--relevance for partial lipodystrophy.
暂无分享,去创建一个
J. Klein | A. Rudich | N. Bashan | Tanya Tarnovscki | J. Kovsan | B. Meier | Adva Maissel | L. Mazor | S. Ovadia | Alexander Osnis | Liat Hollander
[1] J. H. Houben-Weerts,et al. Regulation of adiponectin secretion by insulin and amino acids in 3T3-L1 adipocytes. , 2008, Metabolism: clinical and experimental.
[2] M. Pirmohamed,et al. Effect of atazanavir and ritonavir on the differentiation and adipokine secretion of human subcutaneous and omental preadipocytes , 2008, AIDS.
[3] K. Kano,et al. Establishment of a preadipocyte cell line derived from mature adipocytes of GFP transgenic mice and formation of adipose tissue , 2008, Cell and Tissue Research.
[4] L. Heilbronn,et al. Adipose tissue macrophages, low grade inflammation and insulin resistance in human obesity. , 2008, Current pharmaceutical design.
[5] M. Christian,et al. Conditionally immortalized white preadipocytes: a novel adipocyte models⃞s⃞ The online version of this article (available at http://www.jlr.org) contains supplementary data in the form of three figures. Published, JLR Papers in Press, November 28, 2007. , 2008, Journal of Lipid Research.
[6] F. Matsumura,et al. Development of a human adipocyte model derived from human mesenchymal stem cells (hMSC) as a tool for toxicological studies on the action of TCDD , 2008, Biological chemistry.
[7] M. Uebayasi,et al. Induction of adiponectin by natural and synthetic phenolamides in mouse and human preadipocytes and its enhancement by docosahexaenoic acid. , 2008, Life sciences.
[8] R. Blumer. Regulation of adiponectin secretion by insulin and amino acids in 3 T 3L 1 adipocytes 2 , 2008 .
[9] A. Rudich,et al. Adipose stress-sensing kinases: linking obesity to malfunction , 2007, Trends in Endocrinology & Metabolism.
[10] Y. Kamei,et al. Increased Adiponectin Secretion by Highly Purified Eicosapentaenoic Acid in Rodent Models of Obesity and Human Obese Subjects , 2007, Arteriosclerosis, thrombosis, and vascular biology.
[11] A. Rudich,et al. Regulation of Adipocyte Lipolysis by Degradation of the Perilipin Protein , 2007, Journal of Biological Chemistry.
[12] G. Frühbeck,et al. Visceral and subcutaneous adiposity: are both potential therapeutic targets for tackling the metabolic syndrome? , 2007, Current pharmaceutical design.
[13] M. Stumvoll,et al. Mitogen-activated protein kinases, inhibitory-kappaB kinase, and insulin signaling in human omental versus subcutaneous adipose tissue in obesity. , 2007, Endocrinology.
[14] M. Stumvoll,et al. Macrophage infiltration into omental versus subcutaneous fat across different populations: effect of regional adiposity and the comorbidities of obesity. , 2007, The Journal of clinical endocrinology and metabolism.
[15] U. Smith,et al. Adipose tissue distribution and risk of metabolic disease: does thiazolidinedione-induced adipose tissue redistribution provide a clue to the answer? , 2007, Diabetologia.
[16] André Tchemof. Visceral adipocytes and the metabolic syndrome , 2007 .
[17] A. Shirahata,et al. N-acetylcysteine attenuates TNF-alpha induced changes in secretion of interleukin-6, plasminogen activator inhibitor-1 and adiponectin from 3T3-L1 adipocytes. , 2006, Life sciences.
[18] R. A. Forse,et al. Fat Depot–Specific Characteristics Are Retained in Strains Derived From Single Human Preadipocytes , 2006, Diabetes.
[19] Avner Bar Hen,et al. Increased Infiltration of Macrophages in Omental Adipose Tissue Is Associated With Marked Hepatic Lesions in Morbid Human Obesity , 2006, Diabetes.
[20] Pierre Dupont,et al. Regional Differences in Adipose Tissue Metabolism in Women , 2006, Diabetes.
[21] K. Cianflone,et al. Protease Inhibitor Effects on Triglyceride Synthesis and Adipokine Secretion in Human Omental and Subcutaneous Adipose Tissue , 2005, Antiviral therapy.
[22] V. Manganiello,et al. Effects of the human immunodeficiency virus-protease inhibitor, ritonavir, on basal and catecholamine-stimulated lipolysis. , 2005, The Journal of clinical endocrinology and metabolism.
[23] M. Kalia,et al. Neurobiological basis of depression: an update. , 2005, Metabolism: clinical and experimental.
[24] R. Bergman,et al. Molecular evidence supporting the portal theory: a causative link between visceral adiposity and hepatic insulin resistance. , 2005, American journal of physiology. Endocrinology and metabolism.
[25] G. Bray,et al. Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. , 2005, Metabolism: clinical and experimental.
[26] F. Brun-Vézinet,et al. Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV‐infected patients , 2004, HIV medicine.
[27] A. Rudich,et al. Nelfinavir-induced insulin resistance is associated with impaired plasma membrane recruitment of the PI 3-kinase effectors Akt/PKB and PKC-ζ , 2004, Diabetologia.
[28] J. Hrebícek,et al. Gender differences in tumor necrosis factor alpha and leptin secretion from subcutaneous and visceral fat tissue. , 2004, Physiological research.
[29] M. Desai,et al. Obesity is associated with macrophage accumulation in adipose tissue. , 2003, The Journal of clinical investigation.
[30] L. Tartaglia,et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. , 2003, The Journal of clinical investigation.
[31] H. Lodish,et al. Standard Isolation of Primary Adipose Cells from Mouse Epididymal Fat Pads Induces Inflammatory Mediators and Down-regulates Adipocyte Genes* , 2003, Journal of Biological Chemistry.
[32] R. Garg,et al. Indinavir uncovers different contributions of GLUT4 and GLUT1 towards glucose uptake in muscle and fat cells and tissues , 2003, Diabetologia.
[33] A. Carr. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management , 2003, AIDS.
[34] A. Rudich,et al. Agent and cell-type specificity in the induction of insulin resistance by HIV protease inhibitors , 2003, AIDS.
[35] C. Tinelli,et al. Bcl-2 expression is moderately correlated with long-term variability of CD4 T-cell increase under successful highly active antiretroviral therapy. , 2003, AIDS.
[36] C. Montague,et al. Adipose depot‐specific effects of PPARγ agonists: a consequence of differential expression of PPARγ in adipose tissue depots? , 2002 .
[37] D. Giannella‐Neto,et al. Depot-specific hormonal characteristics of subcutaneous and visceral adipose tissue and their relation to the metabolic syndrome. , 2002, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[38] M. Fasshauer,et al. Novel adipocyte lines from brown fat: a model system for the study of differentiation, energy metabolism, and insulin action. , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.
[39] K. Kristiansen,et al. A Proteomic Approach for Identification of Secreted Proteins during the Differentiation of 3T3-L1 Preadipocytes to Adipocytes* , 2002, Molecular & Cellular Proteomics.
[40] P. Reiss,et al. Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways , 2001, AIDS.
[41] E. Furfine,et al. Metabolic complications associated with antiretroviral therapy. , 2001, Antiviral research.
[42] A. Telenti,et al. Nelfinavir Plasma Levels Under Twice-Daily and Three-Times-Daily Regimens: High Interpatient and Low Intrapatient Variability , 2001, Therapeutic drug monitoring.
[43] I. Harman-boehm,et al. The HIV protease inhibitor nelfinavir induces insulin resistance and increases basal lipolysis in 3T3-L1 adipocytes. , 2001, Diabetes.
[44] C. Vigouroux,et al. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. , 2001, Diabetes.
[45] A. Rudich,et al. Distinct long-term regulation of glycerol and non-esterified fatty acid release by insulin and TNF-α in 3T3-L1 adipocytes , 2001, Diabetologia.
[46] R. D'Agostino,et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[47] C. Flexner,et al. Suppression of Preadipocyte Differentiation and Promotion of Adipocyte Death by HIV Protease Inhibitors* , 2000, The Journal of Biological Chemistry.
[48] J. Klein,et al. Essential Role of Insulin Receptor Substrate-2 in Insulin Stimulation of Glut4 Translocation and Glucose Uptake in Brown Adipocytes* , 2000, The Journal of Biological Chemistry.
[49] P. Hruz,et al. The Mechanism of Insulin Resistance Caused by HIV Protease Inhibitor Therapy* , 2000, The Journal of Biological Chemistry.
[50] J. Klein,et al. Insulin and the beta3-adrenoceptor differentially regulate uncoupling protein-1 expression. , 2000, Molecular endocrinology.
[51] R. Maserati,et al. Clinical pharmacokinetics of nelfinavir combined with efavirenz and stavudine during rescue treatment of heavily pretreated HIV-infected patients. , 2000, The Journal of antimicrobial chemotherapy.
[52] J. Klein,et al. β3-Adrenergic Stimulation Differentially Inhibits Insulin Signaling and Decreases Insulin-induced Glucose Uptake in Brown Adipocytes* , 1999, The Journal of Biological Chemistry.
[53] T. Saruta,et al. Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes. , 1999, Metabolism: clinical and experimental.
[54] N. Tajima,et al. Effect of troglitazone on body fat distribution in type 2 diabetic patients. , 1999, Diabetes care.
[55] A. Rudich,et al. Oxidative Stress Disrupts Insulin-induced Cellular Redistribution of Insulin Receptor Substrate-1 and Phosphatidylinositol 3-Kinase in 3T3-L1 Adipocytes , 1999, The Journal of Biological Chemistry.
[56] M. Lean,et al. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. , 1999, Diabetes care.
[57] A. Rudich,et al. Prolonged oxidative stress impairs insulin-induced GLUT4 translocation in 3T3-L1 adipocytes. , 1998, Diabetes.
[58] S. O’Rahilly,et al. Depot-related gene expression in human subcutaneous and omental adipocytes. , 1998, Diabetes.
[59] M. Digirolamo,et al. Qualitative regional differences in adipose tissue growth and cellularity in male Wistar rats fed ad libitum. , 1998, American journal of physiology. Regulatory, integrative and comparative physiology.
[60] Johan Auwerx,et al. Depot-Specific Differences in Adipose Tissue Gene Expression in Lean and Obese Subjects , 1998, Diabetes.
[61] A. Rudich,et al. Oxidant stress reduces insulin responsiveness in 3T3-L1 adipocytes. , 1997, The American journal of physiology.
[62] O. MacDougald,et al. Regulated expression of the obese gene product (leptin) in white adipose tissue and 3T3-L1 adipocytes. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[63] Yasuhiro Watanabe,et al. Wortmannin, a specific phosphatidylinositol 3-kinase inhibitor, inhibits adipocytic differentiation of 3T3-L1 cells. , 1995, Biochemical and biophysical research communications.
[64] P. Valet,et al. Molecular mechanisms underlying regional variations of catecholamine-induced lipolysis in rat adipocytes. , 1995, The American journal of physiology.
[65] C. Russell,et al. Lipoprotein lipase regulation by insulin and glucocorticoid in subcutaneous and omental adipose tissues of obese women and men. , 1993, The Journal of clinical investigation.
[66] J. Pessin,et al. Regulation of the GLUT4/muscle-fat glucose transporter mRNA in adipose tissue of insulin-deficient diabetic rats. , 1993, The Journal of biological chemistry.
[67] V. Cherington,et al. Separation of simian virus 40 large-T-antigen-transforming and origin-binding functions from the ability to block differentiation , 1988, Molecular and cellular biology.